ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Dermavant raises $200m to support tapinarof launch
June 10, 2021Dermavant Sciences has signed a $160m revenue interest purchase and sale agreement for tapinarof with Marathon Asset Management, NovaQuest Capital Management and a third unnamed institutional investor in the US. -
Dermavant sells Tapinarof commercial rights in Japan
January 19, 2020Dermavant Sciences, a subsidiary of Roivant Sciences, has signed an exclusive agreement to sell the development and commercial rights of tapinarof in Japan. -
GSK sells psoriasis/dermatitis therapy to Dermavant
July 16, 2018Tapinarof is an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) which has been evaluated as a topical therapy in multiple Phase I and Phase II studies involving over 800 human subjects. -
GSK sells psoriasis/dermatitis therapy to Dermavant
July 13, 2018GlaxoSmithKline has sold rights to an experimental therapy with potential in psoriasis and dermatitis to Dermavant in a deal worth $330 million.
Pharma Sources Insight January 2025
